Cover Image

PBPK perspective on alternative CYP3A4 inducers for rifampin

Saved in:

Bibliographic Details
Main Authors:	Kuan‐Fu Chen (Author), Hannah M. Jones (Author)
Format:	Book
Published:	Wiley, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
by: Hengbang Wang, et al.
Published: (2024)

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin
by: Nicolas Hohmann, et al.
Published: (2024)

Understanding CYP3A4 and P‐gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib
by: Christine Bowman, et al.
Published: (2024)

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
by: Darcy J. Mulford, et al.
Published: (2023)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
by: Jayaprakasam Bolleddula, et al.
Published: (2021)

Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework
by: Aneesh V. Karkhanis, et al.
Published: (2024)

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies
by: Jayaprakasam Bolleddula, et al.
Published: (2022)

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling
by: Felix Huth, et al.
Published: (2022)

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6
by: A Ke, et al.
Published: (2016)

<it>CYP3A4 </it>and <it>CYP3A5 </it>genotyping by Pyrosequencing
by: McLeod Howard L, et al.
Published: (2005)

The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity
by: Zhuo-Qing Li, et al.
Published: (2018)

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance
by: Ali Darwich, et al.
Published: (2021)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
by: Jan Grzegorzewski, et al.
Published: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation
by: Jeong-Min Lee, et al.
Published: (2024)

Development and application of a PBPK modeling strategy to support antimalarial drug development
by: Nada Abla, et al.
Published: (2023)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
by: David Damoiseaux, et al.
Published: (2022)

Resveratrol Suppresses the Inducible Expression of CYP3A4 Through the Pregnane X Receptor
by: Rongrong Deng, et al.
Published: (2014)

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia
by: Sh. P. Abdullaev, et al.
Published: (2024)

Refractory bullous pemphigoid improved by discontinuation of phenytoin as an CYP3A4 inducer
by: Rei Yokoyama, et al.
Published: (2020)

How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
by: Qianhui Hua, et al.
Published: (2021)

PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile
by: Karen Rowland Yeo, et al.
Published: (2023)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
by: Hong Ting Shi, et al.
Published: (2021)

Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer
by: Sm Faysal Bellah, et al.
Published: (2023)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
by: Denisenko NP, et al.
Published: (2018)

Expression of CYP3A4 mRNA Is Correlated With CYP3A4 Protein Level and Metabolic Activity in Human Liver
by: Minoru Watanabe, et al.
Published: (2004)

Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5
by: Joseph M. Collins, et al.
Published: (2022)

Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum
by: Decker BS, et al.
Published: (2013)

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen
by: Toshimichi Nakamura, et al.
Published: (2018)

Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis
by: Suting Chen, et al.
Published: (2017)

Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
by: Kevin P. Magee, et al.
Published: (1996)

Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?
by: Nora Renz, et al.
Published: (2021)

Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro
by: Xiao-Yang Zhou, et al.
Published: (2019)

Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients
by: Jolly Kuriakose, et al.
Published: (2022)

Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4
by: Liu W, et al.
Published: (2015)

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
by: Matthias Hoch, et al.
Published: (2022)

Hepatoprotective activity of the ethanol extract of Curcuma heyneana rhizome on isoniazid and rifampin-induced liver injury rats
by: Marianne Marianne, et al.
Published: (2020)

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
by: Md Kabir, et al.
Published: (2022)

Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9
by: Yanding Su, et al.
Published: (2023)

Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin
by: Marwah E. Alnewais, et al.
Published: (2023)